Compare MBBC & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | PLUR |
|---|---|---|
| Founded | 1902 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 33.9M |
| IPO Year | N/A | 2001 |
| Metric | MBBC | PLUR |
|---|---|---|
| Price | $14.00 | $3.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 1.8K | ★ 6.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | $47.11 | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $9.94 | $2.82 |
| 52 Week High | $14.64 | $7.13 |
| Indicator | MBBC | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 44.88 |
| Support Level | $10.05 | $3.13 |
| Resistance Level | N/A | $3.42 |
| Average True Range (ATR) | 0.25 | 0.17 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 66.14 | 18.95 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.